Payment overview · 2025
General Payments
$704.16
37 reported records · 14 companies
Healthcare provider profile · identity verified
Roger E Bowles, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLETON, CO · NPI 1063473965
Verified facts
What the public records show
CMS Open Payments records show Roger E Bowles, MD received $704.16 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.62 | 23.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.34 | 10.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.43 | 9.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $61.23 | 8.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.10 | 8.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.78 | 7.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.76 | 6.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.52 | 5.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.04 | 4.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $30.48 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.00 | 3.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.69 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.50 | 2.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.67 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $704.16 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $90.75 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.50 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.43 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $61.23 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.78 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.76 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $34.04 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 392 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 101 |
| Lisinopril | Lisinopril | 202 | 59 |
| Losartan Potassium | Losartan Potassium | 197 | 59 |
| Simvastatin | Simvastatin | 180 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 40 |
| Eliquis | Apixaban | 135 | 31 |
| Metformin Hcl | Metformin Hcl | 121 | 35 |
| Alprazolam | Alprazolam | 112 | 28 |
| Gabapentin | Gabapentin | 108 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 33 |
| Trazodone Hcl | Trazodone Hcl | 101 | 32 |
| Allopurinol | Allopurinol | 100 | 34 |
| Alendronate Sodium | Alendronate Sodium | 93 | 26 |
| Omeprazole | Omeprazole | 90 | 32 |
| Potassium Chloride | Potassium Chloride | 86 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 25 |
| Synthroid | Levothyroxine Sodium | 79 | 21 |
| Tramadol Hcl | Tramadol Hcl | 79 | 23 |
| Furosemide | Furosemide | 71 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | 16 |
| Azithromycin | Azithromycin | 70 | 55 |
| Prednisone | Prednisone | 70 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 14 |
| Diazepam | Diazepam | 52 | 13 |
| Lovastatin | Lovastatin | 52 | 14 |
| Meloxicam | Meloxicam | 52 | 20 |
| Lorazepam | Lorazepam | 51 | 21 |
| Metformin Hcl Er | Metformin Hcl | 47 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Sertraline Hcl | Sertraline Hcl | 45 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 32 |
| Atenolol | Atenolol | 43 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Ozempic | Semaglutide | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 23 |
| Glipizide | Glipizide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 18 |
| Cefuroxime | Cefuroxime Axetil | 28 | 20 |
| Cephalexin | Cephalexin | 26 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Finasteride | Finasteride | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Neurontin | Gabapentin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $704.16 · 37 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Flector, JARDIANCE, KISUNLA, Kerendia, Licart, MOUNJARO, NEXIUM, NEXLETOL, NURTEC ODT, PREVNAR 20, QULIPTA, Sunosi, TRELEGY ELLIPTA, Tirosint, UBRELVY, VYNDAQEL, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error